We are live on ! Find out more
VTGN icon

VistaGen Therapeutics
VTGN

28 hedge funds and large institutions have $2.39M invested in VistaGen Therapeutics in 2020 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 2

150% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 2

80% more capital invested

Capital invested by funds: $1.33M → $2.39M (+$1.06M)

12% more funds holding

Funds holding: 25 → 28 (+3)

0.02% less ownership

Funds ownership: 0.16% → 0.15% (-0.02%)

Holders
28
Holders Change
+3
Holders Change %
+12%
% of All Funds
0.56%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
6
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$538K
2
Goldman Sachs
Goldman Sachs
New York
+$97.5K
3
Renaissance Technologies
Renaissance Technologies
New York
+$77.3K
4
Two Sigma Advisers
Two Sigma Advisers
New York
+$19.9K
5
Northern Trust
Northern Trust
Illinois
+$18K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$39.5K
2
Jane Street
Jane Street
New York
-$38K
3
SCM
Sitrin Capital Management
California
-$23K
4
DADC
D.A. Davidson & Co
Montana
-$18.3K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$1.36M +$538K +25,992 +67%
Geode Capital Management
2
Geode Capital Management
Massachusetts
$175K – – –
Osaic Holdings
3
Osaic Holdings
Arizona
$119K – – –
Goldman Sachs
4
Goldman Sachs
New York
$99K +$97.5K +4,712 New
DADC
5
D.A. Davidson & Co
Montana
$96K -$18.3K -884 -16%
HighTower Advisors
6
HighTower Advisors
Illinois
$92K – – –
Renaissance Technologies
7
Renaissance Technologies
New York
$86K +$77.3K +3,735 +938%
Northern Trust
8
Northern Trust
Illinois
$74K +$18K +870 +33%
Carson Wealth (CWM LLC)
9
Carson Wealth (CWM LLC)
Nebraska
$43K – – –
LPL Financial
10
LPL Financial
California
$35K +$6.91K +334 +25%
Parallax Volatility Advisers
11
Parallax Volatility Advisers
California
$31K – – –
BlackRock
12
BlackRock
New York
$23K – – –
Two Sigma Advisers
13
Two Sigma Advisers
New York
$20K +$19.9K +960 New
RC
14
RBF Capital
California
$17K – – –
FAIM
15
Financial Advocates Investment Management
Washington
$16K – – –
UBS Group
16
UBS Group
Switzerland
$14K -$39.5K -1,908 -74%
GBA
17
Garrison Bradford & Associates
New York
$14K – – –
TRCT
18
Tower Research Capital (TRC)
New York
$13K +$4.66K +225 +55%
Two Sigma Investments
19
Two Sigma Investments
New York
$13K +$13.2K +637 New
HFM
20
Hartford Financial Management
Connecticut
$11K – – –
Commonwealth Equity Services
21
Commonwealth Equity Services
Massachusetts
$9K – – –
Morgan Stanley
22
Morgan Stanley
New York
$9K – – –
NA
23
NewEdge Advisors
Louisiana
$8K +$8.28K +400 New
JMPWA
24
JP Morgan Private Wealth Advisors
California
$7K – – –
NAS
25
Nicolet Advisory Services
Wisconsin
$7K +$6.89K +333 New
1
2

VTGN Hedge Fund Activity: Q3 2020 in Review

28 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q3 2020, worth a combined $2.39M — up 80% from $1.33M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new VTGN positions and 2 closed out — a net gain of 3 holders — while 6 added to existing stakes and 2 trimmed.

The largest buyer was Vanguard Group, adding an estimated $538K. The largest seller was UBS Group, cutting an estimated $39.5K.

  • 28 institutional investors held VistaGen Therapeutics (VTGN) as of Q3 2020, up from 25 in Q2 2020.
  • Funds reported $2.39M of VistaGen Therapeutics stock for Q3 2020, up 80% quarter-over-quarter.
  • 5 funds opened new VistaGen Therapeutics positions in Q3 2020 and 2 closed out, a net change of +3 holders.
  • The largest VistaGen Therapeutics buyer in Q3 2020 was Vanguard Group, an estimated $538K added.
  • The largest VistaGen Therapeutics seller in Q3 2020 was UBS Group, an estimated $39.5K sold.

Based on aggregated 13F filings for Q3 2020.